Targeting Tuberculosis

Woolcock Institute of Medical Research partner with Pharmaxis, a medical device company with a high-payload inhaler, to develop novel approaches to treat Tuberculosis. Members of the Respiratory Technology and Respiratory and Environmental Epidemiology groups at the Woolcock are working together to develop an inhalable therapy for TB to be used in developed and developing countries.